Top 10 GLP-1 Peptides and Alternatives in 2026: Ranked by Weight Loss Results

A few years ago, losing 15–25% of body weight with a single weekly injection would have sounded like science fiction. In 2026, it is the clinical reality for millions of people using GLP-1 receptor agonists and their next-generation cousins. But the category has expanded far beyond Ozempic. There are now triple agonists outperforming everything before them, compounded versions that make access affordable, and GLP-1 adjacent peptides that work through entirely different but complementary mechanisms.

This guide ranks the 10 most relevant compounds — branded, compounded, and research peptides — based on published clinical data, mechanism potency, dosing convenience, and 2026 real-world availability. For each compound, we cover the mechanism, clinical results, typical protocol, and — critically — how to store it properly, because storage failure is the most common and most preventable way to destroy results.

The Rankings: GLP-1 Peptides and Alternatives by Weight Loss Results

#1 — Retatrutide: Triple Agonist, Maximum Fat Loss

Mechanism: Retatrutide is the most powerful weight loss compound in clinical development. It is a triple agonist that simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. The glucagon receptor activation is the key differentiator — it dramatically increases energy expenditure while GLP-1 suppresses appetite and GIP improves insulin sensitivity. The result is a compound that attacks fat loss from three angles at once: eat less, burn more, and partition fuel better.

Clinical Results: In Eli Lilly's Phase 2 trial, retatrutide at the 12mg dose produced an average of 24.2% body weight reduction at 48 weeks. That is not a typo. No compound in the history of obesity pharmacology has matched that number outside of bariatric surgery.

Typical Protocol: Weekly subcutaneous injection. Phase 2 doses ranged from 1mg to 12mg weekly, with titration over several months. Phase 3 trials are ongoing as of 2026, and compounded versions have begun appearing in research and telehealth channels.

Storage Requirements: Store refrigerated at 2–8°C (36–46°F). Protect from light at all times. Compounded vials are stable for approximately 28–60 days once reconstituted depending on the compounding pharmacy's formulation. Unreconstituted lyophilized powder can last 12–24 months refrigerated. Because retatrutide vials are almost exclusively encountered as compounded multi-dose vials, a dedicated storage case is essential — a single dropped or heat-exposed vial at these concentration levels is a significant financial loss. See our full retatrutide storage guide for protocol-specific advice.

#2 — Tirzepatide: Dual Agonist, Proven and Widely Available

Mechanism: Tirzepatide is a dual GLP-1/GIP agonist. The GIP component adds significant muscle preservation and additional insulin sensitization beyond what GLP-1 alone achieves. This is why tirzepatide's body composition results are notably better than semaglutide's — people lose more fat relative to muscle. GIP receptors are expressed on adipocytes (fat cells) directly, so the dual agonism drives fat loss through both central appetite suppression and peripheral fat cell signaling.

Clinical Results: The SURMOUNT-1 trial at 15mg produced 20.9% average body weight loss at 72 weeks. The SURPASS trials showed even stronger glycemic outcomes for T2D patients. Tirzepatide is currently the most clinically validated weight loss drug widely available through both branded channels (Mounjaro/Zepbound) and compounding pharmacies.

Typical Protocol: Weekly subcutaneous injection. Titration typically starts at 2.5mg and escalates every 4 weeks up to the target dose (5mg, 10mg, or 15mg). Branded versions come as auto-injector pens; compounded versions come as multi-dose vials.

Storage Requirements: Store refrigerated at 2–8°C. Branded pens are stable at room temperature (up to 30°C) for 21 days once removed from refrigeration — useful for travel, but the clock is ticking. Compounded tirzepatide vials should stay refrigerated continuously. Protect from light. Shelf life for compounded vials is typically 28–90 days reconstituted, depending on formulation. Do not freeze. For complete storage protocols, see our tirzepatide storage guide.

#3 — Semaglutide 2.4mg (Wegovy): The Weight Loss Benchmark

Mechanism: Semaglutide is a GLP-1 receptor agonist with an extended half-life engineered via fatty acid chain modification, allowing once-weekly dosing. It works primarily through central appetite suppression (acting on the hypothalamus and brainstem), slowed gastric emptying, and improved insulin sensitivity. At the 2.4mg dose approved for chronic weight management, it delivers meaningfully stronger results than the 1.0mg Ozempic dose used for T2D.

Clinical Results: The STEP 1 trial produced 14.9% body weight reduction at 68 weeks with 2.4mg weekly semaglutide. This was the clinical result that convinced the medical establishment that pharmaceutical-grade obesity treatment had arrived. Wegovy is the branded version; compounded semaglutide offers the same molecule at significantly lower cost.

Typical Protocol: Weekly subcutaneous injection. Titration from 0.25mg over 16–20 weeks to reach the 2.4mg maintenance dose. Administered via auto-injector pen (branded) or multi-dose vial with insulin syringe (compounded).

Storage Requirements: Store refrigerated at 2–8°C. Wegovy pens can be stored at room temperature up to 30°C for 28 days. Compounded semaglutide vials must stay refrigerated continuously. Light sensitive — store in original packaging or an opaque case. Shelf life for compounded vials is typically 28–90 days. See our semaglutide and Ozempic storage guide.

#4 — Semaglutide 1.0mg (Ozempic): The Most-Prescribed GLP-1

Mechanism: Identical molecule to Wegovy — same GLP-1 receptor agonist — but at a lower dose approved for type 2 diabetes management. The mechanism is the same (central appetite suppression, delayed gastric emptying, improved insulin secretion), but the lower dose produces less pronounced weight loss. Still the single most prescribed GLP-1 agonist globally due to physician familiarity and T2D indication.

Clinical Results: In SUSTAIN-6 and related trials, 1.0mg weekly semaglutide produced 6.5% average body weight loss. Significantly less than Wegovy, but with considerable individual variation — some patients see 10%+ at 1.0mg.

Typical Protocol: Weekly subcutaneous injection, starting at 0.25mg and titrating to 0.5mg or 1.0mg. Comes as a multi-dose auto-injector pen.

Storage Requirements: Identical to Wegovy — refrigerate at 2–8°C, stable at room temperature up to 30°C for 56 days once in use. Do not freeze. Light sensitive.

#5 — Liraglutide (Victoza/Saxenda): The Original Daily GLP-1

Mechanism: Liraglutide was the first GLP-1 agonist widely used for weight management. It has a shorter half-life than semaglutide, requiring daily injection. Works through the same GLP-1 receptor mechanism — appetite suppression, delayed gastric emptying, improved glycemic control — but with less receptor coverage per week compared to the long-acting semaglutide.

Clinical Results: The SCALE Obesity trial at 3.0mg (Saxenda dose) showed 5–8% body weight loss at 56 weeks. Still clinically meaningful, but clearly outclassed by newer agents. Remains in use due to established safety record, physician comfort, and some insurance coverage advantages.

Typical Protocol: Daily subcutaneous injection. Titration from 0.6mg/day over 5 weeks to reach 3.0mg/day. Multi-dose auto-injector pen.

Storage Requirements: Store refrigerated at 2–8°C. Once in use, stable at room temperature (15–30°C) for 30 days. Do not freeze. Protect from light. The daily injection requirement means more frequent handling — the pen should be stored in a consistent, cool location between uses.

#6 — Compounded Semaglutide: Same Molecule, Fraction of the Cost

Mechanism: Chemically identical to Ozempic and Wegovy. Compounded semaglutide is produced by FDA-registered 503B compounding pharmacies using semaglutide base or semaglutide sodium. The mechanism is precisely the same GLP-1 receptor agonism — there is no pharmacological difference when properly compounded and stored.

Clinical Results: By definition identical to branded semaglutide data when the compound is properly formulated and stored. Real-world results depend heavily on storage quality — degraded peptide means reduced potency and worse outcomes.

Typical Protocol: Weekly subcutaneous injection drawn from a multi-dose vial using an insulin syringe. Dosing titration follows the same schedule as branded versions. The significant difference is that you are handling open vials repeatedly, which makes storage protocol far more important.

Storage Requirements: This is where compounded semaglutide diverges critically from branded versions. Multi-dose vials must be refrigerated at 2–8°C continuously. There is no built-in auto-injector pen to protect the remaining dose — every time you draw from the vial, you introduce a small air space and potential contamination risk. Vials are light sensitive and should never be left in direct sunlight or warm environments. Typical shelf life is 28–90 days from date of compounding. A dedicated case that holds multiple vials securely, at consistent temperature, with light protection is not optional — it is fundamental to getting clinical-grade results from compounded semaglutide. Read our full compounded semaglutide storage guide for the complete protocol, including what temperatures to avoid and how to inspect vials for degradation.

#7 — Compounded Tirzepatide: The Telehealth Boom Compound

Mechanism: Identical to Mounjaro and Zepbound — GLP-1/GIP dual agonist. Compounded tirzepatide has exploded in availability through telehealth platforms in 2025–2026, making the 20.9% clinical weight loss result accessible at a price point that Eli Lilly's branded product does not reach. Same pharmacology, same mechanism, dramatically different cost structure.

Clinical Results: Equivalent to SURMOUNT-1 data when properly formulated and stored. Individual results vary based on dose achieved and protocol adherence.

Typical Protocol: Weekly subcutaneous injection from a multi-dose vial. Titration begins at 2.5mg and escalates every 4 weeks. Users draw their dose using an insulin syringe — this requires the vial to remain available, refrigerated, and sterile across multiple weekly uses over a 30–90 day vial lifespan.

Storage Requirements: Refrigerate at 2–8°C continuously. Do not allow to freeze. Protect from light. Multi-dose vials that are repeatedly accessed are particularly vulnerable to temperature excursions during the draw process — pulling a vial out of the refrigerator repeatedly over months means each access is a potential exposure event. A structured case that keeps the vial organized, protected, and easily accessible reduces unnecessary handling time and protects the remaining peptide. See the GLP-1 storage guide for tirzepatide and semaglutide for side-by-side storage comparison.

#8 — AOD-9604: The Fat Oxidation Fragment

Mechanism: AOD-9604 is a synthetic fragment of human growth hormone — specifically amino acids 176–191 of the hGH C-terminus — engineered to isolate hGH's fat-metabolizing properties without affecting blood glucose or IGF-1 levels. It works by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage) through a mechanism that mimics beta-3 adrenergic stimulation in adipose tissue. Crucially, it does not suppress appetite — this is not a GLP-1 compound — but it is often used alongside GLP-1 agonists as a targeted fat oxidation adjunct.

Clinical Results: Phase 2 clinical trials in the early 2000s showed modest direct fat loss effects as a standalone (3–4% reduction in abdominal fat), but the compound's value in 2026 is primarily as a stack component alongside GLP-1 agents where it contributes targeted adipose reduction without additional appetite suppression side effects.

Typical Protocol: 250–500mcg subcutaneous injection, once to twice daily, typically on an empty stomach. Research peptide, not FDA-approved. Used in research and biohacking contexts. Comes exclusively as lyophilized powder requiring reconstitution.

Storage Requirements: Store lyophilized powder at 2–8°C refrigerated, or frozen at -20°C for long-term storage (up to 24 months). Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Highly light sensitive — always store in an amber or opaque vial cover. See the AOD-9604 storage guide for reconstitution and stability details.

#9 — CJC-1295 + Ipamorelin: The GH Stack for Fat Loss

Mechanism: This combination stack works through growth hormone stimulation rather than GLP-1 agonism. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that extends the growth hormone pulse duration. Ipamorelin is a GHRP (growth hormone-releasing peptide) that triggers GH release selectively without the cortisol or prolactin spikes seen with older GHRPs. Together, they produce a synergistic, clean GH pulse that drives lipolysis — the process by which fat cells release stored fatty acids for fuel. This is indirect fat loss through hormonal optimization rather than direct appetite suppression.

Clinical Results: No large-scale weight loss RCTs equivalent to the GLP-1 trials, but extensive research on GH-stimulating peptides consistently shows improvements in body composition — specifically fat mass reduction and lean mass preservation — over 12–24 week protocols. Real-world body recomp results are strong when combined with resistance training and caloric management.

Typical Protocol: CJC-1295 (without DAC) 100–300mcg + Ipamorelin 100–300mcg, injected subcutaneously 2–3 times daily, typically before bed and/or first thing in the morning on an empty stomach. Each compound comes as separate lyophilized vials requiring individual reconstitution, or pre-mixed from some compounders.

Storage Requirements: Both compounds are lyophilized powders. Store unreconstituted at 2–8°C or frozen (-20°C) for up to 24 months. Once reconstituted, refrigerate at 2–8°C and use within 30 days. Light sensitive. The twice-daily dosing protocol means you will access vials frequently — a structured case that holds both vials simultaneously, protects from light, and keeps them at consistent temperature is essential. See our CJC-1295 + Ipamorelin storage guide and our broader ipamorelin storage guide for compound-specific stability data.

#10 — Melanotan 2: Melanocortin Appetite Suppression

Mechanism: Melanotan 2 (MT-2) is a synthetic analog of alpha-MSH (alpha-melanocyte-stimulating hormone) that activates melanocortin receptors — specifically MC3R and MC4R. MC4R activation in the hypothalamus produces potent appetite suppression through a completely different pathway than GLP-1 agonism. Additionally, MT-2 has been shown to activate MC3R on adipocytes, promoting fat mobilization. It also produces well-known off-target effects (skin tanning via MC1R, and other effects via MC4R) that limit its use but do not negate its metabolic utility as a GLP-1 adjunct for body recomposition protocols.

Clinical Results: Research peptide with no approved indication. Phase 1/2 studies have shown significant reductions in food intake and some reduction in body fat, particularly visceral fat. Most commonly used in research and biohacking contexts as a GLP-1 complement when additional appetite suppression is desired, or as a standalone for body recomp when GLP-1s are contraindicated or unavailable.

Typical Protocol: 0.5–1.0mg subcutaneous injection, typically every 2–3 days. Comes as lyophilized powder requiring reconstitution with bacteriostatic water.

Storage Requirements: Store lyophilized powder refrigerated at 2–8°C, or frozen at -20°C for long-term storage. Once reconstituted, refrigerate at 2–8°C and use within 30 days. Extremely light sensitive — MT-2 degrades rapidly with light exposure, which is ironic given its tanning mechanism. Always store in an opaque or amber container. Protect from heat. A single vial typically covers 14–28 days of dosing, meaning one active vial and one backup should be stored simultaneously.

The Critical Variable Most People Overlook: Compounded GLP-1 Storage

Here is the distinction that matters most for the majority of people reading this in 2026. If you are using a branded auto-injector pen — Wegovy, Ozempic, Mounjaro, Zepbound — the storage situation is relatively forgiving. The pens have limited room-temperature stability windows, but they are self-contained, single-use-dose devices that minimize contamination and degradation risks.

If you are using compounded semaglutide or compounded tirzepatide — which describes the majority of people accessing GLP-1 therapy at an affordable price point in 2026 — you are managing multi-dose vials that require dedicated storage infrastructure. These are not pens. They are glass vials containing a full month or more of peptide that must be accessed weekly (or more frequently during titration), kept refrigerated continuously, protected from light at all times, and managed without contamination.

The failure modes are real and common. A vial left on the counter while preparing your injection. A case left in a hot car. A vial stored in a bathroom cabinet where temperature and humidity fluctuate. Each of these scenarios can degrade the peptide, reduce potency below clinical thresholds, and produce worse results — without any visible change to the liquid in the vial.

The solution is purpose-built vial storage. A case designed specifically for 3ml and 10ml peptide vials that provides insulation, light protection, secure vial retention, and organized multi-vial capacity. If you are running a GLP-1 protocol with compounded vials, stack compounds, or multiple agents simultaneously, a dedicated case is not a luxury — it is the infrastructure that makes your protocol work as designed. See our guide to the best GLP-1 storage cases and our roundup of the top 10 GLP-1 storage cases for 2026.

How to Choose the Right Compound for Your Goal

The rankings above reflect clinical weight loss percentages, but the right choice depends on your situation. For maximum clinical fat loss with the most powerful mechanism available, retatrutide leads — see our retatrutide vs. tirzepatide comparison for a head-to-head breakdown. For proven, widely available dual agonism, tirzepatide is the current standard of care in 2026. For the most studied GLP-1 agonist with the longest safety record, semaglutide at 2.4mg is the benchmark. For cost-accessible GLP-1 therapy that requires rigorous storage discipline, compounded semaglutide is the entry point for most people. Read the retatrutide dosing protocol and retatrutide weight loss results if that triple agonist is on your radar.

Whatever compound you choose, store it correctly. The clinical trials that produced these impressive numbers were conducted under controlled, consistent conditions. Replicating those results in the real world requires the same discipline — including storage at the right temperature, in the right environment, in the right case.

This content is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before beginning any peptide or hormone protocol.